Sinovac Biotech Ltd. Completes Immunization Schedule In The Phase I Clinical Trial Of Its Proprietary Avian Influenza Vaccine (H5N1)
BEIJING, April 10 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. announced today that all 120 volunteers in the Phase I clinical trial of its avian influenza vaccine (H5N1) have completed the two shot regimen of either the vaccine or a placebo.
All 120 volunteers (aged 18 - 60 years) in the clinical trial were thoroughly evaluated and medically documented prior to entering the vaccination program. The clinical trial was conducted on a 0 and 28 day dose immunization schedule. Sinovac expects to take blood samples from volunteers to analyze the antibody growth and effectiveness of the vaccine.
Sinovac's CEO, Mr. Weidong Yin commented, ''Everything is progressing as we expected. Teaming up with the China CDC is extremely beneficial. We are working hard together to produce a safe and effective vaccine that I believe will benefit the whole world.''
About Sinovac
Sinovac Biotech Ltd. is a world-class Chinese biopharmaceutical company, focused on research, development and commercialization of vaccines designed to combat human infectious diseases. Sinovac's vaccines include Healive(TM) (hepatitis A), Bilive(TM) (hepatitis B) and Anflu(TM) (influenza). Sinovac has vaccines in clinical trials to combat avian influenza (bird flu) and SARS.
Additional information about Sinovac is available on the Company website, http://www.sinovac.com and the Sinovac Investor Relations website, http://finance.groups.yahoo.com/group/Sinovac_Biotech_IR .
To be added to our distribution list, please email: info@sinovac.com
Safe Harbor Statement
This announcement contains forward-looking statements. These statements are made under the ''safe harbor'' provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as ''will,'' ''expects,'' ''anticipates,'' ''future,'' ''intends,'' ''plans,'' ''believes,'' ''estimates'' and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.
For more information, please contact: Craig H. Bird Segue Investor Relations Tel: +1-215-782-8682 or Toll Free: +1-866-360-8682 (North America) Email: sinovac@verizon.net
Sinovac Biotech Ltd.CONTACT: Craig H. Bird of Segue Investor Relations, +1-215-782-8682 orToll Free, +1-866-360-8682 (North America), or sinovac@verizon.net, forSinovac